Miloš Mlynček

Dr. Miloš Mlynček


Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2009 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ASAlexander Sirotkin
Alexander Sirotkin
DODmitriy Ovcharenko
Dmitriy Ovcharenko
RGRoland Grossmann
Roland Grossmann
MLMarcela Lauková
Marcela Lauková
MMMiloš Mlynček
Miloš Mlynček

28 December 2009 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ASAlexander Sirotkin
Alexander Sirotkin
MLMarcela Lauková
Marcela Lauková
DODmitriy Ovcharenko
Dmitriy Ovcharenko
PBPauline Brenaut
Pauline Brenaut
MMMiloš Mlynček
Miloš Mlynček

4 March 2019 in Molecules
Verified
Journal Article
Open access
PDF file
ALAlena Liskova
Alena Liskova
Peter KubatkaPeter Kubatka
Peter Kubatka
MSMarek Samec
Marek Samec
Pavol ZuborPavol Zubor
Pavol Zubor
MMMiloš Mlynček
Miloš Mlynček
Dietrich BüsselbergDietrich Büsselberg
Dietrich Büsselberg
There is an increasing awareness of the importance of a diet rich in fruits and vegetables for human health. Cancer stem cells (CSCs) are characterized as a subpopulation of cancer cells with aberrant regulation of self-renewal, proliferation or apoptosis leading to cancer progression, invasiveness, metastasis formation, and therapy resistance. Anticancer effects of phytochemicals are also directed to target CSCs. Here we provide a comprehensive review of dietary phytochemicals targeting CSCs. Moreover, we evaluate and summarize studies dealing with effects of dietary phytochemicals on CSCs of various malignancies in preclinical and clinical research. Dietary phytochemicals have a significant impact on CSCs which may be applied in cancer prevention and treatment. However, anticancer effects of plant derived compounds have not yet been fully investigated in clinical research.

20 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Pavol ZuborPavol Zubor
Pavol Zubor
ZDZuzana Dankova
Zuzana Dankova
ZKZuzana Kolkova
Zuzana Kolkova
VHVeronika Holubekova
Veronika Holubekova
DBDušan Braný
Dušan Braný
OGOlga Golubnitschaja
Olga Golubnitschaja
Rho guanosine triphospatases (GTPases) resemble a conserved family of GTP-binding proteins regulating actin cytoskeleton dynamics and several signaling pathways central for the cell. Rho GTPases create a so-called Ras-superfamily of GTPases subdivided into subgroups comprising at least 20 members. Rho GTPases play a key regulatory role in gene expression, cell cycle control and proliferation, epithelial cell polarity, cell migration, survival, and apoptosis, among others. They also have tissue-related functions including angiogenesis being involved in inflammatory and wound healing processes. Contextually, any abnormality in the Rho GTPase function may result in severe consequences at molecular, cellular, and tissue levels. Rho GTPases also play a key role in tumorigenesis and metastatic disease. Corresponding mechanisms include a number of targets such as kinases and scaffold/adaptor-like proteins initiating GTPases-related signaling cascades. The accumulated evidence demonstrates the oncogenic relevance of Rho GTPases for several solid malignancies including breast, liver, bladder, melanoma, testicular, lung, central nervous system (CNS), head and neck, cervical, and ovarian cancers. Furthermore, Rho GTPases play a crucial role in the development of radio- and chemoresistance e.g. under cisplatin-based cancer treatment. This article provides an in-depth overview on the role of Rho GTPases in gynecological cancers, highlights relevant signaling pathways and pathomechanisms, and sheds light on their involvement in tumor progression, metastatic spread, and radio/chemo resistance. In addition, insights into a spectrum of novel biomarkers and innovative approaches based on the paradigm shift from reactive to predictive, preventive, and personalized medicine are provided.

4 April 2007 in Molecular Reproduction and Development
Verified
Journal Article
Closed access
PDF file
OØOlga Østrup
Olga Østrup
JLJozef Laurincik
Jozef Laurincik
BABirthe Avery
Birthe Avery
MMMiloš Mlynček
Miloš Mlynček
HNHeiner Niemann
Heiner Niemann
PMPoul Maddox‐Hyttel
Poul Maddox‐Hyttel

1 November 2005 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
ASAlexander Sirotkin
Alexander Sirotkin
MMMiloš Mlynček
Miloš Mlynček
JKJ. Kotwica
J. Kotwica
AMA.V. Makarevich
A.V. Makarevich
IFI. Florkovičová
I. Florkovičová
LHL. Hetényi
L. Hetényi
Aims: The aim of our in vitro studies was to understand the role of leptin and the insulin-like growth factor I/insulin-like growth factor protein (IGF/IGFBP) system in controlling human ovarian function. Methods: We studied the action of leptin (0, 1, 10, or 100 ng/ml) and immunoneutralization of IGF-I using specific antiserum (0.1%) on the release of progesterone (P), estradiol (E), oxytocin (OT), IGF-I, IGFBP-3, and prostaglandins F (PGF) by these cells using radioimmunoassay/immunoradiometric assay. Results: It was found that leptin stimulated the secretion of OT, IGFBP-3, and PGF. It suppressed the secretion of E and IGF-I, but not P, into the medium. The addition of antiserum against IGF-I decreased IGF-I output, increased P, OT, IGFBP-3, and PGF secretion, and had no effect on E release. Immunoneutralization of IGF-I also prevented or reversed the effects of leptin on P, E, IGF-I, IGFBP-3, PGF, but not on OT. Conclusions: These observations (1) demonstrate that leptin directly controls the secretory activity of human ovarian cells, (2) confirm the involvement of IGF-I in the regulation of ovarian cells, and (3) suggest an inter-relationship between leptin and the IGF/IGFBP system in the control of these functions and the involvement of IGF/IGFBP system in mediating leptin action on the ovary.